1 Stubborn Cloud and 2 Silver Linings for Eli Lilly Stock

If you looked solely at its stock price, you might get the idea that Eli Lilly (NYSE: LLY) is having a bit of an off quarter. Over the past 30 days, its shares fell by about 10%, though they are still up by around 37% so far this year. And, if management is correct, one cloudy trend driving their recent decrease in performance is more likely to stick around than shareholders would prefer.Nonetheless, things aren't anywhere near as bad as they might seem at the moment. And Eli Lilly's cloud also has a pair of silver linings that investors will want to hear about.Lilly's newest cash cow, tirzepatide -- a therapy for type 2 diabetes and weight loss that's sold under the names Mounjaro and Zepbound -- is selling a bit slower than anticipated. Though its total revenue in the U.S. in the third quarter was $7.8 billion, up 46% from a year prior, $1.2 billion of which was derived from sales of Zepbound (the weight loss brand), the market's expectations were even higher.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool